Rando K, Hong KI, Bhagwagar Z, Li CS, Bergquist K, Guarnaccia J, Sinha R.Association of frontal and posterior cortical gray matter volume with time to alcohol relapse: a prospective study. Am J Psychiatry. 2011 Feb;168(2):183-92.
Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci. 2010 May 15;292(1-2):28-35.
Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stüve O, Racke M, Frohman EM Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009 Apr;256(4):568-76.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009 Feb 10;72(6):535-41
Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies:distinctive features of a rare disease. Neurology. 2008 Dec 9;71(24):1955-8.
Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag BM; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vrs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomized, parallel, open-label trial. Lancet Neurol. 2008 Oct;7(10):90314
Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W,Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M; CHAMPIONS Study Group. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology.2006 Mar 14;66(5):678-84.
Guarnaccia JB, O’Connor T, Aslan M, Hope MA, Kasis L, Kashner CM, Booss J. Comparing health self-assessments of veterans with multiple sclerosis with standard disability measures. Journal of Rehabilitation Research & Development: Jan/Feb 2006; vol. 43,1:35-44.
Champs Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002; 59:998-1005
Champs Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Multiple Sclerosis 2002;8:330-338.
Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel P, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, and Sandrock AW, CHAMPS Study Group.Interferon B-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. 2002;51:481-490.
Champs Study Group. Interferon B-1a for optic neuritis patients at high risk for multiple sclerosis. Am. J. of Opthalmology. 2001;132:463-471.
Wolinsky JS, Narayana PA, Johnson KP and the Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis (2001) 7, 33-41.
Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel P, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, and Sandrock AW, CHAMPS Study Group.Interferon B-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. 2002;51:481-490.
Champs Study Group. Interferon B-1a for optic neuritis patients, Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS and the Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetatein relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis (2000) 6, 255-266.
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownsheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW, and CHAMPS Study Group. Intramuscular Interferon Beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. NEJM 2000;343:898-904.
Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a mult-center controlled trial. Cladribine MRI Study Group. Neurology 2000; 54(5):1145-55. Mar. 14.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, PanitchHS, rose JW, Schiffer RB, Vollmer T, Winer LP, Wolinsky JS, and the Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708.
Cook SD, Devereux C, Troiano R, Wolansky L, Guarnaccia J, Haffty B, Bansil S, Goldstein J, Sheffet A, Zito G, Jotkowitz A, Boos J, Dowling P, Rohowsky-Kochan C, Vollmer T. Modified total lymphoid irradiation and low dose corticosteroids in progressive MS. J. Neurol Sci 1997; 152: 172-181.
Solimena M, Dirkx, R, Butler M, Hermel J-M, Guarnaccia JB, Marek K, David C., DeCamilli P. Stiff-man syndrome and glutamic acid decarboxylase: an updated view. GABA Symposium ’95. Satellite Meeting of the 15th Biennial Meeting of the International Society for Neurochemistry. Kyoto, Japan. July, 1995.Vollmer T, Guarnaccia J, Harrington Wm, Pacia S, Petroff O. Idiopathic granulomatous angitis of the central nervous system: diagnostic challenges. Arch Neurol 1993; 50:925-930.
Holloway S, Fayad P, Kalb R, Guarnaccia J, Waxman S. Painless aortic dissection: acase study. J. Neurol Sci 1993; 120:141-144.
Slater L, Makintubee S, Istre G, Guarnaccia J. Bactermic disease in adults due to Haemophilus influenzae capsular type f: a report of 5 cases and a survey of the literature. Reviews of Infectious Diseases 1990; July-August.
Interferon beta-1b neutralizing antibodies in MS patients block JAK-STAT signaling pathways. Xie B, Rinder HM, Qin H, Fu XY, Guarnaccia JB. Submitted January 2000.
Rice GPA, for the Cladribine Clinical Study Group, and Filippi M and Comi G for the Cladribine MRI Study Group. Cladribine and progressive MS. Clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000;54:1145-1155.
Cook SD, Devereux C, Troiano R, Wolansky L, Guarnaccia JB, Haffty B, Bansil S, Goldstein J, Sheffet A, Zito G, Jotkowitz A, Boos J, Dowling P, Rohowsky-Kochan C, Vollmer T. Modified total lymphoid irradiation and low dose corticosteroids in progressive MS. J. Neurol Sci 1997; 152: 172-181.
Solimena M, Dirkx, R, Butler M, Hermel J-M, Guarnaccia JB, Marek K, David C., DeCamilli P. Stiff-man syndrome and glutamic acid decarboxylase: an updated view. GABA Symposium '95. Satellite Meeting of the 15th Biennial Meeting of the International Society for Neurochemistry. Kyoto, Japan. July, 1995.
Vollmer T, Guarnaccia J, Harrington Wm, Pacia S, Petroff O. Idiopathic granulomatous angitis of the central nervous system: diagnostic challenges. Arch Neurol 1993; 50:925-930.
Holloway S, Fayad P, Kalb R, Guarnaccia J, Waxman S. Painless aortic dissection: a case study. J. Neurol Sci 1993; 120:141-144.
Slater L, Makintubee S, Istre G, Guarnaccia J. Bactermic disease in adults due to Haemophilus influenzae capsular type f: a report of 5 cases and a survey of the literature. Reviews of Infectious Diseases 1990; July-August.